Trial intelligence / Profile preview

Avelumab plus Cetuximab Rechallenge in RAS/BRAF Wild-Type Metastatic Colorectal Cancer

2024-519481-44-00Phase 2Authorised

Sponsor: Gruppo Oncologico dell'Italia Meridionale
Start: Jan 2025
Modality: Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised trial of avelumab and cetuximab in metastatic colon cancer (mCRC) (2 arms), sponsored by Gruppo Oncologico dell'Italia Meridionale. Primary endpoint: Overall survival. Planned start Jan 2025; status: authorised.

Drugs

avelumabcetuximab

Conditions

metastatic colon cancer (mCRC)

Beyond the preview

Go deeper on 2024-519481-44-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-519481-44-00.